GlassScriptPhysician profile
Sarah E Rhodes
NPI 1962818377
$1,929.51
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $139 · 2021: $107 · 2022: $80.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $225.45 | 2019-2020 | |
| Abbvie INC. | $202.57 | 2019-2022 | |
| Novo Nordisk INC | $182.60 | 2019-2020 | |
| Pfizer INC. | $171.32 | 2019-2020 | |
| Glaxosmithkline, LLC. | $143.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $134.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $129.17 | 2019 | |
| Lilly USA, LLC | $127.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.11 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $94.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.06 | 2019-2020 | |
| Sanofi Pasteur INC. | $43.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $38.31 | 2019 | |
| Mannkind Corporation | $36.99 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.95 | 2019 | |
| Allergan, INC. | $30.66 | 2019 | |
| Amarin Pharma, INC. | $25.00 | 2019 | |
| Daiichi Sankyo INC. | $19.35 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.97 | 2021 | |
| Abbott Laboratories | $14.14 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2019 | |
| Astellas Pharma US INC | $11.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.